Subscribe to Search results

In notes on an informal meeting with the DHSS, Clive Collins noted that the HTLV-3 viral inactivation studies needed to be repeated.

Published on:

Dr Alfred Prince, an eminent virologist, had conducted viral inactivation tests on Armour's product.

Published on:

Dr Prince reported in his findings after conducting viral inactivation tests on Armour's product that higher inactivation process efficacy could not be demonstrated in this experiment due to the unexpectedly low titer of the virus stock employed.

Published on:

In a letter, Armour had learned that a batch of heat-treated Factorate, to which a donor who had subsequently developed AIDS was known to have contributed, had been distributed to eight centres in the UK.

Published on:

Alpha Pharmaceuticals disclosed the results of tests which showed that their heating processes had inactivated HTLV-3/HIV virus load to a degree sufficient to show they were effectively safe. This information was published in a leaflet disclosed to patients.

Published on:

Armour was informed that a patient in Lewisham had seroconverted after receiving a dose from a heat treated batch and noted that "This patient is the first to show sero-conversion from HTLV-III negative to positive following administration of the batch of Factorate Heat Treated in question".

Published on:

Dr Peter Jones told a conference in Newcastle of suspected seroconversions of HIV after using the Armour produced Factor 8 in the Netherlands and the US.

Published on:

Dame Contreras told the Inquiry that with hindsight, testing could have started in July 1991 or earlier, once the second-generation tests were available.

Published on:

Dr Barbara told the Inquiry that with hindsight, he did not believe there was any reason (provided they received the RIBAs) why the testing of the second generation tests couldn't have occurred in parallel with the introduction of testing for all donations.

Published on:

Dr Boulton told the Inquiry that he felt there was an ethical need to introduce Hepatitis C screening at the earliest opportunity, and that it was shameful that "the UK was among the latest countries in Europe" to introduce testing.

Published on:

Dr Huw Lloyd's evidence to the Inquiry was that Dr Gunson never communicated to him that there was a funding reason holding up the commencement of screening.

Published on:

Dr Perry recalled that Dr Metters was concerned that all the details had to be correct before the bigger in principle decision could be made on HCV screening.

Published on:

Dr Rejman expected the PHLS would soon publish the results of their experience of Chiron testing of presumed non-A non-B Hepatitis samples, and would be making a recommendation for use of this test in this publication in September 1989.

Published on:

It was the preference, but not a formal requirement, that the test be licensed in the US by the FDA before being adopted for use in the UK.

Published on:

There was a shift in the NHS funding model which took place in 1991, from centralised and area funding provided by the Department of Health and regional health authorities, to an internal market system.

Published on:

John Canavan stated that reference to the HCV screening being marginal in terms of cost benefit by the Department of Health related to the economic cost-benefit and not the public health benefit.

Published on:

There was HCV testing under development and Dr Gunson and Dr Barbara were told that clinical trials would soon begin. They agreed to conduct a UK study, with 1,000 samples to be sent from the UK to Chiron for blind testing.

Published on:

Dr Gunson wrote to Dr M E Smith to agree to conduct a UK study, with 1,000 samples to be sent from the UK to Chiron for blind testing relating to HCV.

Published on:

A report by Dr Barbara drafted the relevant protocols for the provision of testing kits and to undertake anti-HCV testing on samples for discussion at a further meeting with Ortho on 29 March 1989.

Published on:

Professor Cash wrote to Dr Gunson to ask whether Dr Barbara might be persuaded to include SNBTS samples which had been tested for ALT in the North London Blood Transfusion Centre anti-HCV screening trial.

Published on: